Complement C3 is a novel plasma clot component with anti-fibrinolytic properties

Joanna Marie Howes, Victoria R. Richardson, Kerrie A. Smith, Verena Schroeder, Riyaz Somani, Anna Shore, Katharina Hess, Ramzi Ajjan, Richard J. Pease, Jeffrey N. Keen, Kristina F. Standeven, Angela M. Carter

Research output: Contribution to journalArticlepeer-review

68 Citations (Scopus)


Background and method: Increased plasma clot density and prolonged lysis times are associated with cardiovascular disease. In this study, we employed a functional proteomics approach to identify novel clot components which may influence clot phenotypes. Results: Analysis of perfused, solubilised plasma clots identified inflammatory proteins, including complement C3, as novel clot components. Analysis of paired plasma and serum samples confirmed concentration-dependent incorporation of C3 into clots. Surface plasmon resonance indicated high-affinity binding interactions between C3 and fibrinogen and fibrin. Turbidimetric clotting and lysis assays indicated C3 impaired fibrinolysis in a concentration-dependent manner, both in vitro and ex vivo. Conclusion: These data indicate functional interactions between complement C3 and fibrin leading to prolonged fibrinolysis. These interactions are physiologically relevant in the context of protection following injury and suggest a mechanistic link between increased plasma C3 concentration and acute cardiovascular thrombotic events.

Original languageEnglish
Pages (from-to)216-225
Number of pages10
JournalDiabetes and Vascular Disease Research
Issue number3
Publication statusPublished - 17 Jan 2012
Externally publishedYes


  • Complement C3
  • fibrin
  • fibrinolysis
  • inflammation
  • thrombosis


Dive into the research topics of 'Complement C3 is a novel plasma clot component with anti-fibrinolytic properties'. Together they form a unique fingerprint.

Cite this